Floatz logo

Amantadine

Levodopa Induced Dyskinesia

Adamas Pharmaceuticals, Inc.Small moleculePhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Levodopa Induced Dyskinesia cohort.

Asset / SponsorPhaseRating
Keppra
1st Hospital of Social Security Services
Phase 2CCC

Same molecule, other indications

Amantadine is also rated in:

drug-induced dyskinesiaDormant
BBB
Indicative ·
72 / 100
View asset →
Parkinson diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →